Global sales of Pfizer’s coronavirus vaccine and treatment drove the drug maker into new territory in the first quarter of 2022 as profit grew 61 percent on the back of a 77 percent overall revenue leap.
The New York-based Pfizer Inc. reported Tuesday the coronavirus vaccine Comirnaty delivered more than $13 billion in sales while the treatment Paxlovid added another $1.5 billion as company revenue swelled 77 percent.
AP reports Pfizer also revised its 2022 earnings forecast to reflect an accounting policy change. It now expects adjusted earnings of $6.25 to $6.45 per share.
Producers of the Pfizer vaccine, BioNTech, last year stood amongst the first manufacturers to push for clearance to vaccinate children five and older as the company announced it was ready to begin making smaller doses for children younger than 12.
Producers of the Pfizer vaccine, BioNTech, are preparing to request clearance to vaccinate children five years old and older. https://t.co/A96g6iOLah
— Breitbart News (@BreitbartNews) September 13, 2021
full story at https://www.breitbart.com/health/2022/05/03/big-pharma-is-booming-pfizer-boasts-q1-profit-leap-of-61/